Please upgrade your browser.
Arginase is an enzyme in myeloid-derived suppressor cells (MDSCs), which prevents T-cell and natural killer (NK) cell activation in tumors.
The new dosage regimen is for 240mg IV every 2 weeks until disease progression or intolerable toxicity for renal cell carcinoma...
Bi-allelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney
Cell lines (CAKI-1, HK2 or A704) were either transfected with 2 independent siRNAs or non-target controls.
The drug, cabometyx, is approved for patients in advanced stages of the disease who have already received prior treatment. The drug was approved by the U.S.'s Food and Drug Administration in April.
Advanced tumors may have met their match with new drugs, but why have these treatments proved ineffective at stopping early-stage tumors from coming back?
Siegel hopes that these findings will encourage investigators to find out the "driving forces behind these increases."
In rare circumstances, a person with sickle cell trait may develop a rare kidney cancer called renal medullary carcinoma.
High BMI is a prognostic factor for improved survival and progression-free survival in patients with metastatic RCC...
Summary of "Hereditary leiomyomatosis and renal cell cancer syndrome: identification and clinical characterization of a novel mutation in the FH gene in a Colombian family."
Children, adolescents or young adults, particularly African-Americans, diagnosed with advanced kidney cancer may actually have a rare form of the disease known as renal medullary carcinoma (RMC) that requires a specialized approach and expert intervention.
|NeonCRM by Neon One|